thrive holistic glp-1 How Medications Are Revolutionizing Weight Loss MyGLP: Wellness made easy. 💚

This approach benefits employees by allowing more flexible, customized coverage and benefits employers by improving cost control, transparency, and the ability to offer innovative healthcare solutions while managing financial risk

In March 2024, Viking Therapeutics announced positive results from the company's Phase I multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735 , a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, in development for the potential treatment of metabolic disorders such as obesity

The majority of clinical studies have been funded or co-funded by the manufacturer, and sample sizes remain modest (typically 20 to 40 subjects)

Image Credit: Visual Capitalist Data: S&P global, GLP-1 Men, Financial times, IFEBP & Reuters #biotech #biopharma #GLP1 #obesity Im finishing an article on how to build the next GLP-1